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The concept of adult immunization is difficult for
many of the general population and of the physi-
cian population alike to perceive as important. In
reality, the immunization of pediatric-age patients
is largely an accepted fact and ongoing process but
adultscanfindmanyreasonstoneglectthemselves.
Many physicians are aware that hepatitis B virus
(HBV) poses a significant health risk to patients
who become infected with this virus. The inci-
dence of HBV infection in the United States is
rising despite the availability of effective strategies.
Current estimates of the incidence of HBV infec-
tion suggest approximately 300 000 new cases
annuallyoranincreaseof37%inthelast20years.
In the US, adolescents and adults account for
the majority of new cases. Over 95% of otherwise
healthy adults and older children who acquire
HBV recover from the infection and suffer no
long-lasting effects. In contrast, children infected
undertheageof1yearhavea90%chanceofdevel-
oping chronic infection and those under 5 years
have a 40–50% chance. Children who become
infected with HBV are at a disproportionate risk
for the development of major complications
including chronic hepatitis with cirrhosis and liver
failure, fulminant hepatitis and hepatocellular
carcinoma. HBV vaccine is truly the first cancer
vaccine.
During the late 1970s, hepatitis B immune
globulin (HBIG) was administered to neonates
within the first 2 days of life. This strategy
prevented neonatal acquisition of the virus and
the administration of HBV vaccine given in
combination with HBIG not only prevented
infection in infancy but conveyed lasting protec-
tion in over 95% of treated infants. The current
strategy developed by the Centers for Disease
Control (CDC) includes recommendations for
universal screening of all pregnantwomen early in
pregnancy and repeated screening of women who
are at high risk of HBV infection, i.e. intravenous
drug users and those with intercurrent sexually
transmitted diseases or clinically evident hepatitis.
It is strongly recommended that the first dose of
HBV vaccine should be given in the hospital prior
to discharge. Data fromTable1indicatethat initial
protection is present with just one dose. The
recommended hepatitis B vaccine schedule is seen
in Table 2.
A number of hospitals and health plans have
backed away from initiation of HBV vaccination
in the newborn nursery. This is a tragic turn of
events in the effort to immunize all persons. Each
physician must examine his/her own hospital’s
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Dose number Infants Teens and adults
1
2
3
16–40%
80–95%
98–100%
20–30%
75–80%
90–95%
Table 1 Protection available after each dose of
hepatitis B vaccine. Data from Margolis HS, Alter MJ,
Hadler SC. Semin Liver Dis 1991;11:84–92
1policy because the policy may have changed with-
outtheinvolved physiciansbeingalerted.Wemust
therefore insist on universal screening of all preg-
nant women, as well as universal administration of
the first HBV vaccine dose in the newborn
nursery.
REFERENCES
1. Margolis HS, Alter MJ, Hadler SC. Hepatitis B:
evolving epidemiologyand implications for control.
Semin Liver Dis 1991;11:84–92
Hepatitis B virus immunization Gall
64 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY
When to administer HBIG and HBV vaccine to your infant patients
Patient history HBIG HBV dose 1 HBV dose 2 HBV dose 3
Infant born to HbsAg-positive
mother
Preterm infant born to
HbsAg-positive mother
Infant born to HbsAg-negative
mother and at high risk of
early childhood infection*
Infant born to mother not tested
for HbsAg** and mother is later
found to be HbsAg positive
Infant born to mother not tested
for HbsAg** and mother is later
found to be HbsAg negative
Preterm infant born to
HbsAg-negative mother
Infant born to HbsAg-negative
mother and at low risk of early
childhood infection
Give within 12
hours of birth
Give within
12 hours
of birth
No
Give ASAP
before 7
days of age
No
No
No
Give within 12 hours of birth
Give dose 1 within 12 hours
of birth. If infant weighs less
than 2 kg at birth, repeat
dose 1 when infant weighs
2 kg or is 2 months of age
Preferably give dose 1 at
birth but give no later than
2 months of age
Give within 12 hours of birth
Give within 12 hours of birth
Give when infant weighs 2 kg
or at 2 months old
Give at birth–2 months of age
Give at 1–2
months of age
Give 1–2
months after
the previous
dose
Give 1–4
months of age
Give at 1–2
months of age
Give at 1–2
months of age
Give at 1–4
months of age
Give at 1–4
months of age
Give at 6 months of
age
Give at 6 months of
age
Give at 6 months of
age or no later than
12 months of age
Give at 6 months of
age
Give at 6–18
months of age
Give at 6–18 months
of age. Infants at
high risk of
infection need dose
3 no later than 12
months of age
Give at 6–18
months of age
*Infants born to HbsAg-negative mothers who are at risk of early childhood HBV infection include infants whose mothers belong to
populations and groups from areas of moderate and high endemicity for HBV infection. Areas of high endemicity (‡ 8% HBV carrier rate)
include Africa; Southeast Asia including China, Korea, Indonesia, and the Philippines; the Middle East except Israel; South and Western
Pacific Islands; interior Amazon Basin; and certain parts of the Caribbean, i.e. Haiti and the Dominican Republic. Alaska natives are also at
high risk. Areas of moderate endemicity (2–7% HBV carrier rate) include South Central and Southwest Asia, Israel, Japan, Eastern and
Southern Europe, Russia, and most of Central and South America. Also, any infant who lives in a household with an HBV carrier should be
considered at high risk for HBV infection; **mothers should have blood drawn for HbsAg testing as soon as possible; HBIG, hepatitis B
immune globulin; ASAP, as soon as possible
Table 2 Recommended hepatitis B (HBV) vaccination timings for infants. Engerix-B
Ò (SmithKline Beecham,
Rixensart, Belgium) and Recombivax HB
Ò (Merck, Whitehouse Station, NJ) are the vaccine products available for use in
the United States. Engerix-B and Recombivax HB single-antigen HBV vaccines are used for the birth dose and can also
be used for all the remaining doses recommended for infants and children